Tirzepatide (Zepbound) vs VK2735

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

Tirzepatide (Zepbound)

Marketed by Eli Lilly

Approved in Obesitypeptide
Reliable signal

NCT04184622 · Phase 3 · completed

SURMOUNT-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 2,539 adults with obesity, or overweight with a weight-related complication, and without diabetes. Participants received weekly tirzepatide 5 mg, 10 mg or 15 mg or placebo for 72 weeks. The co-primary endpoints were the percent change in body weight and the share of participants who lost 5% or more of their weight. In the intention-to-treat analysis, weight fell by 15.0%, 19.5% and 20.9% with the three doses against 3.1% with placebo, and 85% to 91% of tirzepatide participants lost at least 5% against 35% with placebo (P<0.001 for all comparisons), so the trial met its primary endpoints. The figures come from the peer-reviewed paper in the New England Journal of Medicine.

Next expected readout: November 2026 · NCT07299084 (registry estimate)

Reported efficacy

Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21) (met)

Result source: NCT05412004

VK2735

Developed by Viking Therapeutics

Phase 3 in Obesitypeptide
Reliable signal

NCT06828055 · Phase 2 · completed

This randomized, triple-blind, placebo-controlled Phase 2 trial (n=280) in adults with obesity found that oral VK2735 produced significantly greater weight loss than placebo at 13 weeks, up to 12.2% versus 1.3% (placebo-adjusted 10.9%, p<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07838740 (registry estimate)

Reported efficacy

Percent (relative) change from baseline in body weight after 13 weeks of treatment: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 (met)

Result source: NCT06828055

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTirzepatide (Zepbound)VK2735
Body weight, % change-22.5% vs -2.4%−20.1 vs placebo15 mg · wk 72 · n 625NCT04184622
20 other results
  • -15.7% vs -3.3% 15 mg · wk 72 · n 309 · Phase 3 · primary NCT04657003
  • -21.4% vs -2.4% 10 mg · wk 72 · n 629 · Phase 3 · primary NCT04184622
  • -13.4% vs -3.3% 10 mg · wk 72 · n 309 · Phase 3 · primary NCT04657003
  • -16% vs -2.4% 5 mg · wk 72 · n 623 · Phase 3 · primary NCT04184622
  • -6.7% vs 14.8% MTD · wk 88 · n 332 · Phase 3 · primary NCT04660643
  • -21.1% vs 3.3% wk 72 · n 284 · Phase 3 · primary NCT04657016
  • -22.7% vs -1.7% 15 mg · wk 72 · n 65 · Phase 3 · primary NCT04844918
  • -19.9% vs -2.4% 15 mg · wk 52 · n 68 · Phase 3 · primary NCT05024032
  • -17.8% vs -1.7% 10 mg · wk 72 · n 59 · Phase 3 · primary NCT04844918
  • -14.4% vs -2.4% 10 mg · wk 52 · n 70 · Phase 3 · primary NCT05024032
  • -20.2% vs -13.7% 15 mg or MTD · wk 72 · n 318 · Phase 3 · primary NCT05822830
  • -22.9% vs -2.1% 15 mg · wk 176 · n 249 · Phase 3 · secondary NCT04184622
  • -19.9% vs -2.1% 10 mg · wk 176 · n 260 · Phase 3 · secondary NCT04184622
  • -15.4% vs -2.1% 5 mg · wk 176 · n 245 · Phase 3 · secondary NCT04184622
  • -26% vs -9.5% MTD · wk 88 · n 332 · Phase 3 · secondary NCT04660643
  • -6% vs 9.9% MTD · wk 64 · n 332 · Phase 3 · secondary NCT04660643
  • -17.6% vs -2.3% MTD · wk 52 · n 101 · Phase 3 · secondary NCT05412004
  • -19.6% vs -2.3% MTD · wk 52 · n 113 · Phase 3 · secondary NCT05412004
  • -13.8% vs -2.2% MTD · wk 52 · n 331 · Phase 3 · secondary NCT04847557
  • -21.8% vs -15.4% 15 mg or MTD · wk 72 · n 367 · Phase 3 · secondary NCT05822830
—Trial running · NCT07104500
Weight loss of 5% or more96.3% vs 27.9%+68.4 vs placebo15 mg · wk 72 · n 625NCT04184622
12 other results
  • 86.4% vs 30.6% 15 mg · wk 72 · n 309 · Phase 3 · primary NCT04657003
  • 96.2% vs 27.9% 10 mg · wk 72 · n 629 · Phase 3 · primary NCT04184622
  • 81.5% vs 30.6% 10 mg · wk 72 · n 309 · Phase 3 · primary NCT04657003
  • 89.4% vs 27.9% 5 mg · wk 72 · n 623 · Phase 3 · primary NCT04184622
  • 94.4% vs 10.7% wk 72 · n 284 · Phase 3 · primary NCT04657016
  • 96.0% vs 20% 15 mg · wk 72 · n 76 · Phase 3 · primary NCT04844918
  • 92.7% vs 29.4% 15 mg · wk 52 · n 68 · Phase 3 · primary NCT05024032
  • 94.4% vs 20% 10 mg · wk 72 · n 71 · Phase 3 · primary NCT04844918
  • 91.4% vs 29.4% 10 mg · wk 52 · n 70 · Phase 3 · primary NCT05024032
  • 94.8% vs 24.6% 15 mg · wk 176 · n 249 · Phase 3 · secondary NCT04184622
  • 91.9% vs 24.6% 10 mg · wk 176 · n 260 · Phase 3 · secondary NCT04184622
  • 90.6% vs 24.6% 5 mg · wk 176 · n 245 · Phase 3 · secondary NCT04184622
—Trial running · NCT07104500
Weight loss of 10% or more90.1% vs 13.5%+76.5 vs placebo15 mg · wk 72 · n 625NCT04184622
10 other results
  • 69.6% vs 8.7% 15 mg · wk 72 · n 309 · Phase 3 · secondary NCT04657003
  • 85.8% vs 13.5% 10 mg · wk 72 · n 629 · Phase 3 · secondary NCT04184622
  • 63.4% vs 8.7% 10 mg · wk 72 · n 309 · Phase 3 · secondary NCT04657003
  • 73.3% vs 13.5% 5 mg · wk 72 · n 623 · Phase 3 · secondary NCT04184622
  • 88.0% vs 4.8% wk 72 · n 284 · Phase 3 · secondary NCT04657016
  • 92.1% vs 4% 15 mg · wk 72 · n 76 · Phase 3 · secondary NCT04844918
  • 83.8% vs 14.7% 15 mg · wk 52 · n 68 · Phase 3 · secondary NCT05024032
  • 85.9% vs 4% 10 mg · wk 72 · n 71 · Phase 3 · secondary NCT04844918
  • 70% vs 14.7% 10 mg · wk 52 · n 70 · Phase 3 · secondary NCT05024032
  • 87.7% vs 66.7% 15 mg or MTD · wk 72 · n 318 · Phase 3 · secondary NCT05822830
—Trial running · NCT07104500
Waist circumference, change (cm)-19.9 vs -3.4−16.5 vs placebo15 mg · wk 72 · n 625NCT04184622
12 other results
  • -13.8 vs -3.4 15 mg · wk 72 · n 309 · Phase 3 · secondary NCT04657003
  • -19.4 vs -3.4 10 mg · wk 72 · n 629 · Phase 3 · secondary NCT04184622
  • -11.2 vs -3.4 10 mg · wk 72 · n 309 · Phase 3 · secondary NCT04657003
  • -14.6 vs -3.4 5 mg · wk 72 · n 622 · Phase 3 · secondary NCT04184622
  • -4.6 vs 8.3 MTD · wk 88 · n 332 · Phase 3 · secondary NCT04660643
  • -22.8 vs -9.1 MTD · wk 88 · n 332 · Phase 3 · secondary NCT04660643
  • -16.8 vs 1.1 wk 72 · n 284 · Phase 3 · secondary NCT04657016
  • -16.6 vs -1.3 15 mg · wk 72 · n 65 · Phase 3 · secondary NCT04844918
  • -16.4 vs -2.7 15 mg · wk 52 · n 68 · Phase 3 · secondary NCT05024032
  • -12.7 vs -1.3 10 mg · wk 72 · n 59 · Phase 3 · secondary NCT04844918
  • -11.9 vs -2.7 10 mg · wk 52 · n 70 · Phase 3 · secondary NCT05024032
  • -18.4 vs -13 15 mg or MTD · wk 72 · n 318 · Phase 3 · secondary NCT05822830
—Trial running · NCT07104500

Body weight, % change

Tirzepatide (Zepbound)
-22.5% vs -2.4%−20.1 vs placebo15 mg · wk 72 · n 625NCT04184622
20 other results
  • -15.7% vs -3.3% 15 mg · wk 72 · n 309 · Phase 3 · primary NCT04657003
  • -21.4% vs -2.4% 10 mg · wk 72 · n 629 · Phase 3 · primary NCT04184622
  • -13.4% vs -3.3% 10 mg · wk 72 · n 309 · Phase 3 · primary NCT04657003
  • -16% vs -2.4% 5 mg · wk 72 · n 623 · Phase 3 · primary NCT04184622
  • -6.7% vs 14.8% MTD · wk 88 · n 332 · Phase 3 · primary NCT04660643
  • -21.1% vs 3.3% wk 72 · n 284 · Phase 3 · primary NCT04657016
  • -22.7% vs -1.7% 15 mg · wk 72 · n 65 · Phase 3 · primary NCT04844918
  • -19.9% vs -2.4% 15 mg · wk 52 · n 68 · Phase 3 · primary NCT05024032
  • -17.8% vs -1.7% 10 mg · wk 72 · n 59 · Phase 3 · primary NCT04844918
  • -14.4% vs -2.4% 10 mg · wk 52 · n 70 · Phase 3 · primary NCT05024032
  • -20.2% vs -13.7% 15 mg or MTD · wk 72 · n 318 · Phase 3 · primary NCT05822830
  • -22.9% vs -2.1% 15 mg · wk 176 · n 249 · Phase 3 · secondary NCT04184622
  • -19.9% vs -2.1% 10 mg · wk 176 · n 260 · Phase 3 · secondary NCT04184622
  • -15.4% vs -2.1% 5 mg · wk 176 · n 245 · Phase 3 · secondary NCT04184622
  • -26% vs -9.5% MTD · wk 88 · n 332 · Phase 3 · secondary NCT04660643
  • -6% vs 9.9% MTD · wk 64 · n 332 · Phase 3 · secondary NCT04660643
  • -17.6% vs -2.3% MTD · wk 52 · n 101 · Phase 3 · secondary NCT05412004
  • -19.6% vs -2.3% MTD · wk 52 · n 113 · Phase 3 · secondary NCT05412004
  • -13.8% vs -2.2% MTD · wk 52 · n 331 · Phase 3 · secondary NCT04847557
  • -21.8% vs -15.4% 15 mg or MTD · wk 72 · n 367 · Phase 3 · secondary NCT05822830
VK2735
—Trial running · NCT07104500

Weight loss of 5% or more

Tirzepatide (Zepbound)
96.3% vs 27.9%+68.4 vs placebo15 mg · wk 72 · n 625NCT04184622
12 other results
  • 86.4% vs 30.6% 15 mg · wk 72 · n 309 · Phase 3 · primary NCT04657003
  • 96.2% vs 27.9% 10 mg · wk 72 · n 629 · Phase 3 · primary NCT04184622
  • 81.5% vs 30.6% 10 mg · wk 72 · n 309 · Phase 3 · primary NCT04657003
  • 89.4% vs 27.9% 5 mg · wk 72 · n 623 · Phase 3 · primary NCT04184622
  • 94.4% vs 10.7% wk 72 · n 284 · Phase 3 · primary NCT04657016
  • 96.0% vs 20% 15 mg · wk 72 · n 76 · Phase 3 · primary NCT04844918
  • 92.7% vs 29.4% 15 mg · wk 52 · n 68 · Phase 3 · primary NCT05024032
  • 94.4% vs 20% 10 mg · wk 72 · n 71 · Phase 3 · primary NCT04844918
  • 91.4% vs 29.4% 10 mg · wk 52 · n 70 · Phase 3 · primary NCT05024032
  • 94.8% vs 24.6% 15 mg · wk 176 · n 249 · Phase 3 · secondary NCT04184622
  • 91.9% vs 24.6% 10 mg · wk 176 · n 260 · Phase 3 · secondary NCT04184622
  • 90.6% vs 24.6% 5 mg · wk 176 · n 245 · Phase 3 · secondary NCT04184622
VK2735
—Trial running · NCT07104500

Weight loss of 10% or more

Tirzepatide (Zepbound)
90.1% vs 13.5%+76.5 vs placebo15 mg · wk 72 · n 625NCT04184622
10 other results
  • 69.6% vs 8.7% 15 mg · wk 72 · n 309 · Phase 3 · secondary NCT04657003
  • 85.8% vs 13.5% 10 mg · wk 72 · n 629 · Phase 3 · secondary NCT04184622
  • 63.4% vs 8.7% 10 mg · wk 72 · n 309 · Phase 3 · secondary NCT04657003
  • 73.3% vs 13.5% 5 mg · wk 72 · n 623 · Phase 3 · secondary NCT04184622
  • 88.0% vs 4.8% wk 72 · n 284 · Phase 3 · secondary NCT04657016
  • 92.1% vs 4% 15 mg · wk 72 · n 76 · Phase 3 · secondary NCT04844918
  • 83.8% vs 14.7% 15 mg · wk 52 · n 68 · Phase 3 · secondary NCT05024032
  • 85.9% vs 4% 10 mg · wk 72 · n 71 · Phase 3 · secondary NCT04844918
  • 70% vs 14.7% 10 mg · wk 52 · n 70 · Phase 3 · secondary NCT05024032
  • 87.7% vs 66.7% 15 mg or MTD · wk 72 · n 318 · Phase 3 · secondary NCT05822830
VK2735
—Trial running · NCT07104500

Waist circumference, change (cm)

Tirzepatide (Zepbound)
-19.9 vs -3.4−16.5 vs placebo15 mg · wk 72 · n 625NCT04184622
12 other results
  • -13.8 vs -3.4 15 mg · wk 72 · n 309 · Phase 3 · secondary NCT04657003
  • -19.4 vs -3.4 10 mg · wk 72 · n 629 · Phase 3 · secondary NCT04184622
  • -11.2 vs -3.4 10 mg · wk 72 · n 309 · Phase 3 · secondary NCT04657003
  • -14.6 vs -3.4 5 mg · wk 72 · n 622 · Phase 3 · secondary NCT04184622
  • -4.6 vs 8.3 MTD · wk 88 · n 332 · Phase 3 · secondary NCT04660643
  • -22.8 vs -9.1 MTD · wk 88 · n 332 · Phase 3 · secondary NCT04660643
  • -16.8 vs 1.1 wk 72 · n 284 · Phase 3 · secondary NCT04657016
  • -16.6 vs -1.3 15 mg · wk 72 · n 65 · Phase 3 · secondary NCT04844918
  • -16.4 vs -2.7 15 mg · wk 52 · n 68 · Phase 3 · secondary NCT05024032
  • -12.7 vs -1.3 10 mg · wk 72 · n 59 · Phase 3 · secondary NCT04844918
  • -11.9 vs -2.7 10 mg · wk 52 · n 70 · Phase 3 · secondary NCT05024032
  • -18.4 vs -13 15 mg or MTD · wk 72 · n 318 · Phase 3 · secondary NCT05822830
VK2735
—Trial running · NCT07104500
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

VK2735
Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 NCT06828055 · Phase 2 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Tirzepatide (Zepbound): 4 of 4 rows · VK2735: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTirzepatide (Zepbound)
Dropout rate
8.7%15 mga
NCT04184622 · Phase 3
show 19 more results
11%10 mg
NCT04184622 · Phase 3
9.7%5 mg
NCT04184622 · Phase 3
9.3%15 mg
NCT04657003 · Phase 3
—10 mg
NCT04657003 · Phase 3
12.2%
NCT04657016 · Phase 3
—MTD
NCT04660643 · Phase 3
11.4%MTD
NCT05412004 · Phase 3
5.8%MTD
NCT05412004 · Phase 3
14.9%15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
8.8%MTD
NCT04847557 · Phase 3 · registry result, not featured evidence
27.8%15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
—10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
5.6%15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
—10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
16.7%2.5-5 mg
NCT05696847 · Phase 1 · registry result, not featured evidence
14.3%1.25-2.5 mg
NCT05696847 · Phase 1 · registry result, not featured evidence
14.3%2.5-5 mg
NCT05696847 · Phase 1 · registry result, not featured evidence
16.2%
NCT04311411 · Phase 1 · registry result, not featured evidence
—15 mg
NCT04081337 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
1%15 mga
NCT04184622 · Phase 3
show 19 more results
1.3%10 mg
NCT04184622 · Phase 3
0.6%5 mg
NCT04184622 · Phase 3
1.6%15 mg
NCT04657003 · Phase 3
—10 mg
NCT04657003 · Phase 3
1.4%
NCT04657016 · Phase 3
—MTD
NCT04660643 · Phase 3
0%MTD
NCT05412004 · Phase 3
0.8%MTD
NCT05412004 · Phase 3
1.6%15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
0.3%MTD
NCT04847557 · Phase 3 · registry result, not featured evidence
8.9%15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
—10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
1.4%15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
—10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
0%2.5-5 mg
NCT05696847 · Phase 1 · registry result, not featured evidence
0%1.25-2.5 mg
NCT05696847 · Phase 1 · registry result, not featured evidence
14.3%2.5-5 mg
NCT05696847 · Phase 1 · registry result, not featured evidence
8.1%
NCT04311411 · Phase 1 · registry result, not featured evidence
—15 mg
NCT04081337 · Phase 1 · registry result, not featured evidence
Serious AEs
7.9%15 mga
NCT04184622 · Phase 3
show 19 more results
9.4%10 mg
NCT04184622 · Phase 3
9%5 mg
NCT04184622 · Phase 3
8.7%15 mg
NCT04657003 · Phase 3
5.8%10 mg
NCT04657003 · Phase 3
5.9%
NCT04657016 · Phase 3
3%MTD
NCT04660643 · Phase 3
7.9%MTD
NCT05412004 · Phase 3
5.9%MTD
NCT05412004 · Phase 3
4.8%15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
26.4%MTD
NCT04847557 · Phase 3 · registry result, not featured evidence
6.5%15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
11%10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
11.3%15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
4.3%10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
0%2.5-5 mg
NCT05696847 · Phase 1 · registry result, not featured evidence
0%1.25-2.5 mg
NCT05696847 · Phase 1 · registry result, not featured evidence
0%2.5-5 mg
NCT05696847 · Phase 1 · registry result, not featured evidence
0%
NCT04311411 · Phase 1 · registry result, not featured evidence
3.7%15 mg
NCT04081337 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
15 mga
nausea 31.9% (placebo 9.8%)
diarrhoea 23.7% (placebo 7.9%)
covid-19 17.9% (placebo 16.5%)
NCT04184622 · Phase 3
show 19 more results
10 mg
nausea 34.1% (placebo 9.8%)
diarrhoea 22.5% (placebo 7.9%)
covid-19 20.1% (placebo 16.5%)
NCT04184622 · Phase 3
5 mg
nausea 25.4% (placebo 9.8%)
diarrhoea 20.3% (placebo 7.9%)
covid-19 20.2% (placebo 16.5%)
NCT04184622 · Phase 3
15 mg
nausea 21.9% (placebo 6.3%)
diarrhoea 21.2% (placebo 8.9%)
vomiting 12.9% (placebo 3.2%)
NCT04657003 · Phase 3
10 mg
nausea 20.2% (placebo 6.3%)
diarrhoea 19.9% (placebo 8.9%)
covid-19 16.7% (placebo 16.8%)
NCT04657003 · Phase 3
nausea 39.7% (placebo 14%)
diarrhoea 31% (placebo 9.2%)
constipation 23% (placebo 6.8%)
NCT04657016 · Phase 3
MTD
covid-19 14% (placebo 14.9%)
diarrhoea 10.7% (placebo 4.8%)
nausea 8.1% (placebo 2.7%)
NCT04660643 · Phase 3
MTD
diarrhoea 26.3% (placebo 12.5%)
nausea 25.4% (placebo 10%)
vomiting 17.5% (placebo 4.2%)
NCT05412004 · Phase 3
MTD
diarrhoea 21.8% (placebo 12.5%)
nausea 21.8% (placebo 10%)
constipation 15.1% (placebo 2.5%)
NCT05412004 · Phase 3
15 mg or MTD
nausea 43.6%
constipation 27%
diarrhoea 23.5%
NCT05822830 · Phase 3 · registry result, not featured evidence
MTD
diarrhoea 17.9% (placebo 6.3%)
nausea 17% (placebo 6.3%)
constipation 14.8% (placebo 6%)
NCT04847557 · Phase 3 · registry result, not featured evidence
15 mg
constipation 27.3% (placebo 6.7%)
nausea 23.4% (placebo 4%)
covid-19 19.5% (placebo 17.3%)
NCT04844918 · Phase 3 · registry result, not featured evidence
10 mg
covid-19 20.5% (placebo 17.3%)
constipation 16.4% (placebo 6.7%)
nausea 13.7% (placebo 4%)
NCT04844918 · Phase 3 · registry result, not featured evidence
15 mg
diarrhoea 40.8% (placebo 8.7%)
nausea 32.4% (placebo 5.8%)
decreased appetite 28.2% (placebo 11.6%)
NCT05024032 · Phase 3 · registry result, not featured evidence
10 mg
diarrhoea 40% (placebo 8.7%)
nausea 30% (placebo 5.8%)
decreased appetite 27.1% (placebo 11.6%)
NCT05024032 · Phase 3 · registry result, not featured evidence
2.5-5 mg
decreased appetite 50% (placebo 0%)
nausea 50% (placebo 0%)
constipation 33.3% (placebo 0%)
NCT05696847 · Phase 1 · registry result, not featured evidence
1.25-2.5 mg
nausea 28.6% (placebo 0%)
abdominal pain 14.3% (placebo 0%)
cough 14.3% (placebo 0%)
NCT05696847 · Phase 1 · registry result, not featured evidence
2.5-5 mg
vomiting 85.7% (placebo 0%)
nausea 71.4% (placebo 0%)
abdominal pain 57.1% (placebo 0%)
NCT05696847 · Phase 1 · registry result, not featured evidence
nausea 51.4% (placebo 5.1%)
vomiting 29.7% (placebo 2.6%)
constipation 18.9% (placebo 0%)
NCT04311411 · Phase 1 · registry result, not featured evidence
15 mg
nausea 51.9% (placebo 25%)
constipation 37% (placebo 14.3%)
injection site reaction 37% (placebo 0%)
NCT04081337 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tirzepatide (Zepbound)

Weight -22.5% (n=625) vs -2.4% (n=635) placebo @ 72wk15 mg
percent change · % of baseline
NCT04184622 · Phase 3
show 20 more results
-22.9% (n=249) vs -2.1% (n=264) placebo @ 176wk15 mg
NCT04184622 · Phase 3
-15.7% (n=309) vs -3.3% (n=311) placebo @ 72wk15 mg
NCT04657003 · Phase 3
-20.2% (n=318) vs -13.7% (n=318) Semaglutide @ 72wk15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
-21.8% (n=367) vs -15.4% (n=373) Semaglutide @ 72wk15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
-22.7% (n=65) vs -1.7% (n=66) placebo @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-19.9% (n=68) vs -2.4% (n=68) placebo @ 52wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-21.4% (n=629) vs -2.4% (n=635) placebo @ 72wk10 mg
NCT04184622 · Phase 3
-19.9% (n=260) vs -2.1% (n=264) placebo @ 176wk10 mg
NCT04184622 · Phase 3
-13.4% (n=309) vs -3.3% (n=311) placebo @ 72wk10 mg
NCT04657003 · Phase 3
-17.8% (n=59) vs -1.7% (n=66) placebo @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-14.4% (n=70) vs -2.4% (n=68) placebo @ 52wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-16% (n=623) vs -2.4% (n=635) placebo @ 72wk5 mg
NCT04184622 · Phase 3
-15.4% (n=245) vs -2.1% (n=264) placebo @ 176wk5 mg
NCT04184622 · Phase 3
-21.1% (n=284) vs 3.3% (n=291) placebo @ 72wk
NCT04657016 · Phase 3
-6.7% (n=332) vs 14.8% (n=329) placebo @ 88wkMTD
NCT04660643 · Phase 3
-6% (n=332) vs 9.9% (n=329) placebo @ 64wkMTD
NCT04660643 · Phase 3
-26% (n=332) vs -9.5% (n=329) placebo @ 88wkMTD
NCT04660643 · Phase 3
-17.65% (n=101) vs -1.56% (n=87) placebo @ 52wkMTD
NCT05412004 · Phase 3
-19.62% (n=113) vs -1.56% (n=87) placebo @ 52wkMTD
NCT05412004 · Phase 3
-13.85% (n=331) vs -2.24% (n=333) placebo @ 52wkMTD
NCT04847557 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 96.32% (n=625) vs 27.87% (n=635) placebo @ 72wk15 mg
responder rate · % of participants
NCT04184622 · Phase 3
show 12 more results
94.78% (n=249) vs 24.62% (n=264) placebo @ 176wk15 mg
NCT04184622 · Phase 3
86.41% (n=309) vs 30.55% (n=311) placebo @ 72wk15 mg
NCT04657003 · Phase 3
96.05% (n=76) vs 20% (n=75) placebo @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
92.65% (n=68) vs 29.41% (n=68) placebo @ 52wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
96.18% (n=629) vs 27.87% (n=635) placebo @ 72wk10 mg
NCT04184622 · Phase 3
91.92% (n=260) vs 24.62% (n=264) placebo @ 176wk10 mg
NCT04184622 · Phase 3
81.55% (n=309) vs 30.55% (n=311) placebo @ 72wk10 mg
NCT04657003 · Phase 3
94.37% (n=71) vs 20% (n=75) placebo @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
91.43% (n=70) vs 29.41% (n=68) placebo @ 52wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
89.41% (n=623) vs 27.87% (n=635) placebo @ 72wk5 mg
NCT04184622 · Phase 3
90.61% (n=245) vs 24.62% (n=264) placebo @ 176wk5 mg
NCT04184622 · Phase 3
94.37% (n=284) vs 10.65% (n=291) placebo @ 72wk
NCT04657016 · Phase 3
Weight Loss 10% 90.08% (n=625) vs 13.54% (n=635) placebo @ 72wk15 mg
responder rate · % of participants
NCT04184622 · Phase 3
show 10 more results
69.58% (n=309) vs 8.68% (n=311) placebo @ 72wk15 mg
NCT04657003 · Phase 3
87.7% (n=318) vs 66.7% (n=318) Semaglutide @ 72wk15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
92.11% (n=76) vs 4% (n=75) placebo @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
83.82% (n=68) vs 14.71% (n=68) placebo @ 52wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
85.85% (n=629) vs 13.54% (n=635) placebo @ 72wk10 mg
NCT04184622 · Phase 3
63.43% (n=309) vs 8.68% (n=311) placebo @ 72wk10 mg
NCT04657003 · Phase 3
85.92% (n=71) vs 4% (n=75) placebo @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
70% (n=70) vs 14.71% (n=68) placebo @ 52wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
73.35% (n=623) vs 13.54% (n=635) placebo @ 72wk5 mg
NCT04184622 · Phase 3
88.03% (n=284) vs 4.81% (n=291) placebo @ 72wk
NCT04657016 · Phase 3
Weight Loss 15% 78.24% (n=625) vs 5.98% (n=635) placebo @ 72wk15 mg
responder rate · % of participants
NCT04184622 · Phase 3
show 10 more results
51.78% (n=309) vs 2.57% (n=311) placebo @ 72wk15 mg
NCT04657003 · Phase 3
71.7% (n=318) vs 45% (n=318) Semaglutide @ 72wk15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
82.89% (n=76) vs 1.33% (n=75) placebo @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
72.06% (n=68) vs 2.94% (n=68) placebo @ 52wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
73.61% (n=629) vs 5.98% (n=635) placebo @ 72wk10 mg
NCT04184622 · Phase 3
41.42% (n=309) vs 2.57% (n=311) placebo @ 72wk10 mg
NCT04657003 · Phase 3
63.38% (n=71) vs 1.33% (n=75) placebo @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
48.57% (n=70) vs 2.94% (n=68) placebo @ 52wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
50.24% (n=623) vs 5.98% (n=635) placebo @ 72wk5 mg
NCT04184622 · Phase 3
73.94% (n=284) vs 2.06% (n=291) placebo @ 72wk
NCT04657016 · Phase 3
Weight Loss 20% 62.88% (n=625) vs 1.26% (n=635) placebo @ 72wk15 mg
responder rate · % of participants
NCT04184622 · Phase 3
show 6 more results
33.98% (n=309) vs 0.96% (n=311) placebo @ 72wk15 mg
NCT04657003 · Phase 3
55% (n=318) vs 31.1% (n=318) Semaglutide @ 72wk15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
55.48% (n=629) vs 1.26% (n=635) placebo @ 72wk10 mg
NCT04184622 · Phase 3
22.98% (n=309) vs 0.96% (n=311) placebo @ 72wk10 mg
NCT04657003 · Phase 3
31.62% (n=623) vs 1.26% (n=635) placebo @ 72wk5 mg
NCT04184622 · Phase 3
54.93% (n=284) vs 1.03% (n=291) placebo @ 72wk
NCT04657016 · Phase 3
Waist Circumference Change -19.9 vs -3.4 placebo cm @ 72wk15 mg
absolute change · cm
NCT04184622 · Phase 3
show 12 more results
-13.8 vs -3.4 placebo cm @ 72wk15 mg
NCT04657003 · Phase 3
-18.4 vs -13 Semaglutide cm @ 72wk15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
-16.6 vs -1.3 placebo cm @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-16.4 vs -2.7 placebo cm @ 52wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-19.4 vs -3.4 placebo cm @ 72wk10 mg
NCT04184622 · Phase 3
-11.2 vs -3.4 placebo cm @ 72wk10 mg
NCT04657003 · Phase 3
-12.7 vs -1.3 placebo cm @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-11.9 vs -2.7 placebo cm @ 52wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-14.6 vs -3.4 placebo cm @ 72wk5 mg
NCT04184622 · Phase 3
-16.8 vs 1.1 placebo cm @ 72wk
NCT04657016 · Phase 3
-4.6 vs 8.3 placebo cm @ 88wkMTD
NCT04660643 · Phase 3
-22.8 vs -9.1 placebo cm @ 88wkMTD
NCT04660643 · Phase 3
BMI -8.6 vs -0.9 placebo kg @ 72wk15 mg
absolute change · kg
NCT04184622 · Phase 3
show 12 more results
-5.7 vs -1.2 placebo kg @ 72wk15 mg
NCT04657003 · Phase 3
-8.5 vs -6 Semaglutide kg @ 72wk15 mg or MTD
NCT05822830 · Phase 3 · registry result, not featured evidence
-7.7 vs -0.6 placebo kg @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-6.4 vs -0.8 placebo kg @ 52wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-8.1 vs -0.9 placebo kg @ 72wk10 mg
NCT04184622 · Phase 3
-4.9 vs -1.2 placebo kg @ 72wk10 mg
NCT04657003 · Phase 3
-5.8 vs -0.6 placebo kg @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-4.7 vs -0.8 placebo kg @ 52wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-5.9 vs -0.9 placebo kg @ 72wk5 mg
NCT04184622 · Phase 3
-7.7 vs 1.2 placebo kg @ 72wk
NCT04657016 · Phase 3
-2.1 vs 4.3 placebo kg @ 88wkMTD
NCT04660643 · Phase 3
-10 vs -3.6 placebo kg @ 88wkMTD
NCT04660643 · Phase 3
HbA1c -0.51% (n=608) vs -0.07% (n=612) placebo @ 72wk15 mg
absolute change · percentage points
NCT04184622 · Phase 3
show 12 more results
-2.22% (n=300) vs -0.16% (n=290) placebo @ 72wk15 mg
NCT04657003 · Phase 3
-0.68% (n=40) vs -0.02% (n=47) placebo @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-0.35% (n=66) vs 0.03% (n=67) placebo @ 52wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-0.4% (n=24) vs -0.04% (n=24) placebo @ 18wk15 mg
NCT04081337 · Phase 1 · registry result, not featured evidence
-0.49% (n=607) vs -0.07% (n=612) placebo @ 72wk10 mg
NCT04184622 · Phase 3
-2.14% (n=301) vs -0.16% (n=290) placebo @ 72wk10 mg
NCT04657003 · Phase 3
-0.67% (n=35) vs -0.02% (n=47) placebo @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-0.34% (n=69) vs 0.03% (n=67) placebo @ 52wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-0.4% (n=607) vs -0.07% (n=612) placebo @ 72wk5 mg
NCT04184622 · Phase 3
-0.46% (n=278) vs 0.01% (n=275) placebo @ 72wk
NCT04657016 · Phase 3
-0.08% (n=325) vs 0.25% (n=311) placebo @ 88wkMTD
NCT04660643 · Phase 3
-0.57% (n=325) vs -0.22% (n=311) placebo @ 88wkMTD
NCT04660643 · Phase 3
Fasting Glucose Change mg/dL -10.55 vs 0.86 placebo mg @ 72wk15 mg
absolute change · mg
NCT04184622 · Phase 3
show 8 more results
-51.67 vs -2.42 placebo mg @ 72wk15 mg
NCT04657003 · Phase 3
-10.61 vs 2.19 placebo mg @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-9.73 vs 0.86 placebo mg @ 72wk10 mg
NCT04184622 · Phase 3
-49.2 vs -2.42 placebo mg @ 72wk10 mg
NCT04657003 · Phase 3
-12.81 vs 2.19 placebo mg @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-7.73 vs 0.86 placebo mg @ 72wk5 mg
NCT04184622 · Phase 3
-8.8 vs 2.4 placebo mg @ 72wk
NCT04657016 · Phase 3
-0.9 vs 7.74 placebo mg @ 88wkMTD
NCT04660643 · Phase 3
IWQOL-Lite-CT Physical Function 21.8 vs 10.1 placebo score @ 72wk15 mg
absolute change · score
NCT04184622 · Phase 3
show 11 more results
15.2 vs 7.4 placebo score @ 72wk15 mg
NCT04657003 · Phase 3
13 vs 2.2 placebo score @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
12 vs 3.5 placebo score @ 52wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
20.7 vs 10.1 placebo score @ 72wk10 mg
NCT04184622 · Phase 3
14.3 vs 7.4 placebo score @ 72wk10 mg
NCT04657003 · Phase 3
15.2 vs 2.2 placebo score @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
11.2 vs 3.5 placebo score @ 52wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
17.8 vs 10.1 placebo score @ 72wk5 mg
NCT04184622 · Phase 3
13.9 vs 1.1 placebo score @ 72wk
NCT04657016 · Phase 3
4.4 vs -5 placebo score @ 88wkMTD
NCT04660643 · Phase 3
26 vs 16.7 placebo score @ 88wkMTD
NCT04660643 · Phase 3
Weight -15.6 vs -3.2 placebo kg @ 72wk15 mg
absolute change · kg
NCT04657003 · Phase 3
show 11 more results
-20.8 vs -1.5 placebo kg @ 72wk15 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-11.1 vs -1.8 placebo kg @ 20wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-18.1 vs -2.1 placebo kg @ 52wk15 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-16.73 vs -8.26 placebo kg @ 18wk15 mg
NCT04081337 · Phase 1 · registry result, not featured evidence
-13.5 vs -3.2 placebo kg @ 72wk10 mg
NCT04657003 · Phase 3
-16 vs -1.5 placebo kg @ 72wk10 mg
NCT04844918 · Phase 3 · registry result, not featured evidence
-9 vs -1.8 placebo kg @ 20wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-13.1 vs -2.1 placebo kg @ 52wk10 mg
NCT05024032 · Phase 3 · registry result, not featured evidence
-21.5 vs 3.5 placebo kg @ 72wk
NCT04657016 · Phase 3
-5.7 vs 11.9 placebo kg @ 88wkMTD
NCT04660643 · Phase 3
-27.6 vs -10 placebo kg @ 88wkMTD
NCT04660643 · Phase 3
HbA1c Less Than 7% 90.67% (n=300) vs 29.31% (n=290) placebo @ 72wk15 mg
responder rate · % of participants
NCT04657003 · Phase 3
show 1 more result
90.03% (n=301) vs 29.31% (n=290) placebo @ 72wk10 mg
NCT04657003 · Phase 3

+ 56 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tirzepatide (Zepbound)'s landscape · VK2735's landscape